New study of psoriatic cells could fire up the study of inflammation

May 21, 2010
Inflammatory images. New research homes in on molecules that define the most troublesome of two types of dendritic cells in psoriatic lesions. TRAIL (red) and CD11c (green) are thought to be key molecular contributors to the inflammatory activity of immature dendritic cells, which make up 80 percent to 90 percent of dendritic cells associated with psoriasis.

( -- Psoriasis is one of humanity’s oldest know diseases and one of the more widespread, affecting 2 percent of the U.S. population. But it remains largely a mystery. New work identifies markers that define two types of dendritic cells found in psoriatic lesions, findings that will help scientists isolate and study the most troublesome inflammatory variety.

New research promises to pry some long held secrets from one of humanity’s oldest known diseases. Scientists at Rockefeller University have discovered how to parse the most troublesome behind the debilitating skin lesions in psoriasis and have identified several distinctive markers that suggest how they might be contributing to the disease — a painful inflammation of the skin that afflicts up to 2 percent of the U.S. population.

The work, published online May 14 in the Journal of and Clinical Immunology, focused on special called , which are believed to be fundamental contributors to the disease. Two main types of dendritic cells are found in the lesions — immature dendritic cells, which make up 80 percent to 90 percent of the population, and tissue-resident dendritic cells. Using cell sorting to separate the two types and then gene array analysis to identify the different molecules produced by each kind, researchers found that the immature dendritic cells expressed a host of that differentiated them from the resident dendritic cells.

Among them were molecules known as TNF-related inducing ligand (TRAIL), Toll-Like Receptor (TLR) 1 and 2, and others that could fuel inflammatory pathways, says Michelle Lowes, assistant professor of clinical investigation in the Laboratory of Investigative Dermatology at Rockefeller’s Center for Clinical and Translational Science. Knowing what molecules are active in psoriasis is key to understanding the disease, providing researchers a starting point for looking at genes that might contribute to it, and treatments that might prevent it.

“Different types of dendritic cells are really difficult to tease out,” says Lowes, who worked with biomedical fellow Lisa Zaba and others on the project. “We wanted to publish this list of markers so that other people can look for any of their genes of interest.”

Psoriasis is one of the most common inflammatory diseases and relatively easy to study because samples can be obtained from the skin. Despite its long-known and widespread prevalence, it is not well understood. A deeper knowledge of the inflammatory molecules at work in could help develop treatments not only for the skin disorder but also for diseases ranging from allergies to arthritis and cancer.

Explore further: To spread, skin cancer attacks immune dendritic cells

More information: Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasis , The Journal of Allergy and Clinical Immunology online: May 14, 2010.

Related Stories

To spread, skin cancer attacks immune dendritic cells

May 27, 2009

( -- Dendritic cells are the sentinels of the immune system. When they’re alert and on guard, they will marshal the body’s immunosoldiers, T cells, to battle at the sight of harmful pathogens. But some diseases, ...

New clinical study probes how light fights psoriasis

April 29, 2009

Ultraviolet light is a proven treatment for psoriasis, one of humanity’s oldest known diseases. Sunshine can also beat back the chronic autoimmune disorder of the skin. But explaining light’s therapeutic effects has been ...

Recently discovered cell is unexpected player in psoriasis

November 29, 2007

When the FDA assesses a drug, it looks closely at its safety and its effectiveness, but it doesn’t require a precise understanding of how the drug works. A new study by Rockefeller University scientists shows that a strikingly ...

Small molecules may explain psoriasis

July 11, 2007

A research team at the Swedish medical university Karolinska Institutet has shown for the time that microRNA, small RNA molecules, may play an important role in the development of inflammatory skin diseases such as psoriasis ...

First evidence of native dendritic cells in brain

May 15, 2008

In a finding that has the potential to change the way researchers think about the brain, scientists at Rockefeller University have found dendritic cells where they’ve never been seen before: among this organ’s neurons ...

Recommended for you

How the finch changes its tune

August 3, 2015

Like top musicians, songbirds train from a young age to weed out errors and trim variability from their songs, ultimately becoming consistent and reliable performers. But as with human musicians, even the best are not machines. ...

Cow embryos reveal new type of chromosome chimera

May 27, 2016

I've often wondered what happens between the time an egg is fertilized and the time the ball of cells that it becomes nestles into the uterine lining. It's a period that we know very little about, a black box of developmental ...

Shaving time to test antidotes for nerve agents

February 29, 2016

Imagine you wanted to know how much energy it took to bike up a mountain, but couldn't finish the ride to the peak yourself. So, to get the total energy required, you and a team of friends strap energy meters to your bikes ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.